News Release

Yamanouchi Pharmaceutical Co., Ltd.

LOI Signed between Boehringer Ingelheim and Yamanouchi on Co-Promotion of Angiotensin II Receptor Blocker "Telmisartan"

January 24, 2002

Tokyo, 24 January 2002 - Boehringer Ingelheim GmbH, a global pharmaceutical group of companies, headquartered in Germany, and Yamanouchi Pharmaceutical Co., Ltd. signed a Letter of Intent on the co-promotion of telmisartan (generic name), an angiotensin II receptor antagonist, in Japan.

Telmisartan has been discovered and internationally developed by Boehringer Ingelheim. Nippon Boehringer Ingelheim Co., Ltd. has clinically developed telmisartan in Japan and applied for drug approval in January 2001. Following approval, the product, which will be manufactured by Nippon Boehringer Ingelheim, is going to be jointly marketed by both companies and distributed by Yamanouchi. In close cooperation, the two companies will enhance their activities in providing promotional and scientific information to the medical community and will effectively promote the innovative feature of this product to medical professionals.

Telmisartan is an angiotensin II receptor blocker for the treatment of hypertension alone or in combination with other antihypertensive agents.
International clinical data indicate that the compound has excellent benefits (both efficacy and safety), and controls when given once daily blood pressure over a 24 hour period - especially during the early morning hours, the period of the day with the highest risk for myocardial events.

Telmisartan is on the market under the trademark of Micardis® in over 67 countries, including the U.S.A. and major European countries around the world.

Company Profiles

Nippon Boehringer Ingelheim Co., Ltd.
Establishment: June 1961
Head Office: 3-10-1, Kawanishi-shi, Hyogo, Japan
Chairman & President: Prof. Christoph Hohbach
Net Sales: 77.8 billion yen (as of March 2001)
Number of Employees: 1,407 (as of 1st April 2001)
Major Business: •Research & development, import, manufacturing, and marketing of pharmaceuticals
  •Import/export and marketing of pharmaceutical active ingredients and intermediates
  •Import and marketing of health food


Boehringer Ingelheim GmbH(
Establishment: 1885
Head Office: Ingelheim, Germany
Representative: Prof. Rolf Krebs (Chairman of the Board)
Consolidated Net Sales: EUR 6,188 million (as of December 2000) / about 680 billion yen
Consolidated Number of Employees: about 27,500
Major Business:

Research & Development, manufacturing, and marketing of prescription medicine, consumer healthcare products, animal health product, bio-pharmaceuticals, and chemicals

Operation Sites: 140 sites around the world


Yamanouchi Pharmaceutical Co., Ltd. (
Establishment: April 1923
Head Office: 3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
President: Toichi Takenaka
Consolidated Net Sales: about 458 billion yen (as of March 2001)
Consolidated Number of Employees: about 9,300
Major Business: Manufacture and Marketing of Pharmaceuticals, Quasi Drugs, Food, and Medical Devices.


<for reference>

•The renin-angiotensin system

Renin (a kind of enzyme) excreted from kidneys converts angiotensinogen (a kind of protein) produced in the liver to angiotensin I in the blood. Further, angiotensin I is converted to angiotensin II by angiotensin converting enzyme (ACE) in the lungs or plasma.
Recently, other than the above pathway, an angiotensin II production in local tissues (heart, blood vessel wall, kidney, brain, adrenal gland, liver, intestines), and a production that is independent from angiotensin converting enzyme(ACE) have been confirmed.


•Angiotensin II receptor blocker

Angiotensin II is a peptide possessing a strong pressor action. Angiotensin II exhibits its functions by binding to angiotensin II receptors in the body (type 1 and type 2). When angiotensin II binds to type 1 receptors it causes the blood vessels to contract, and blood pressure to rise. It is believed that type 1, which is broadly existed cardiovascular tissues and kidney, receptors participate in the body such as blood vessel contraction and cell proliferation, while type 2 receptors have actions such as blood vessel dilation and anti-cell proliferation action. Angiotensin II receptor blocker selectively block type 1 receptors, bringing about a hypotensive action for hypertension patients.

Renin-angiotensin system, and angiotensin II receptor blocker